Jonathan Wygant Appointed Chief Accounting Officer at Veracyte

Veracyte Inc. has appointed Jonathan Wygant as chief accounting officer. He now oversees all aspects of the company’s global accounting operations, financial reporting and tax functions, and reports to Rebecca Chambers, Veracyte’s chief financial officer.
 
“We are thrilled to welcome Jonathan to Veracyte,” said Chambers. “He brings a depth of expertise and experience leading accounting operations for a range of healthcare companies, including global organizations. As we advance our global strategic vision, his accounting leadership will be critical to ensuring our organization’s continued success.”
 
Wygant most recently served as corporate controller at Biosplice Therapeutics Inc. (formerly Samumed LLC), a clinical-stage biotechnology company. In this role, he led all finance, accounting and reporting functions within the company. Prior to that, Wygant was the chief financial officer at Cibus Global LLC, where he supervised the company’s financial operations. He also served as vice president, controller and chief accounting officer at Alere Inc., a point-of-care diagnostics company that was acquired by Abbott in 2016. Prior to that, Wygant held various leadership roles at CareFusion, including senior vice president, controller and chief accounting officer.
 
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco.